Abbott Laboratories Stock News

(Reuters) – Abbott Laboratories said on Thursday it was recalling powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who consumed the products.

Abbott Laboratories said on Thursday it was recalling powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who consumed the products.

Abbott Laboratories said late Thursday it is voluntarily recalling powder baby formulas, including its best-selling Similac, made in one plant in Michigan after it received four consumer complaints related to the bacteria Cronobacter sakazakii or Salmonella Newport in infants who had consumed powder infant formula made in the factory. "During testing in our Sturgis, Mich., facility, we found evidence of Cronobacter sakazakii in the plant in non-product contact areas. We found no evidence of Salmonella Newport. This investigation is ongoing," Abbott said. "Importantly, no distributed product has tested positive for the presence of either of these bacteria, and we continue to test." Despite detecting no pathogens, the company is recalling powder formulas manufactured in the plant with an expiration of April 1, 2022 or after, it said. The recall does not affect Abbott liquid formulas, powder formulas, or nutrition products from other facilities, Abbott said. "We''re taking this action so parents know they can trust us to meet our high standards, as well as theirs.

Abbott Laboratories said on Thursday it was recalling powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who c

Abbott Laboratories ABT, -2.51% said late Thursday it is voluntarily recalling powder baby formulas, including its best-selling Similac, made in one plant in Michigan after it received four consumer c

This longtime winner still has bright prospects ahead of it.

This longtime winner still has bright prospects ahead of it.

Pune, Feb. 17, 2022 (GLOBE NEWSWIRE) -- " Final Report will add the analysis of the impact of COVID-19 on this industry. " Global " Spinal Implants and Surgery Devices Market " is a comprehensive research that provides information regarding Spinal Implants and Surgery Devices market size, trends, growth, cost structure, capacity, revenue, and forecast for 2027. This report also includes the overall study of the Spinal Implants and Surgery Devices Market share with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Spinal Implants and Surgery Devices industry and provides data for making strategies to increase Spinal Implants and Surgery Devices market growth and effectiveness. The report further investigates and assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the Spinal Implants and Surgery Devices market. The global Spinal Implants and Surgery Devices market size is projected to reach US$ 13440 million by 2027, from US$ 9529.7 million in 2020, at a CAGR of 5.0% during 2021-2027.

Don't worry about Humira's impending loss of exclusivity in the U.S.

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

WASHINGTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- In recent years more than 15.5 Million people globally develop pressure injuries, which are one of the most common complications occurring in hospitals. Although these injuries can be treated by conventional methods of treatment by regular patient turning. A wearable patient sensor is used to optimize turning practices and improve clinical outcomes. Wearable patient sensors are currently used among major hospitals and have extraordinary benefits such as cost effectiveness, patient monitoring advantages, increased productivity, and many more. Hence using wearable patient sensor in modern healthcare system is expected to generate large revenue in coming years, states Vantage Market Research, in a report, titled " Wearable Patient Sensor Market by Product (Pressure Sensor, Temperature Sensor, Position Sensor, Other Types), by Application (Smart Wristwear, Smart Glasses, Smart Bodywears, Smart Footwears), by End User (Healthcare, Consumer Electronic, Sports/Fitness, Other End-user Verticals), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

I own things that outperform in down markets; I don't diversify in the traditional sense, instead diversify against different specific risks; I don't use a benchmark but have personal goals.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.